Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

279.00
BATS BZX Real-Time Price
As of 3:43pm ET
 +6.06 / +2.22%
Today’s Change
242.07
Today|||52-Week Range
420.99
-8.93%
Year-to-Date
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.
May 24 / MotleyFool.com - Paid Partner Content
Stock Market News for May 13, 2016
May 13 / Zacks.com - Paid Partner Content
The Best Buys in Biopharma Today
May 24 / MotleyFool.com - Paid Partner Content
Perrigo (PRGO) Tops Q1 Earnings, 2016 Earnings View Intact
May 12 / Zacks.com - Paid Partner Content
Jeff Auxier's Spring 6 Market Commentary
May 20 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close272.94
Today’s open273.51
Day’s range273.51 - 279.39
Volume52,393
Average volume (3 months)1,800,920
Market cap$59.8B
Dividend yield--
Data as of 3:43pm ET, 05/25/2016

Growth & Valuation

Earnings growth (last year)+24.01%
Earnings growth (this year)+10.91%
Earnings growth (next 5 years)+9.50%
Revenue growth (last year)-3.87%
P/E ratio17.1
Price/Sales7.60
Price/Book6.37

Competitors

 Today’s
change
Today’s
% change
BXLTBaxalta Inc+0.60+1.33%
BAXBaxter International...-0.18-0.41%
GILDGilead Sciences+0.35+0.41%
JUNOJuno Therapeutics In...-0.17-0.42%
Data as of 3:43pm ET, 05/25/2016

Financials

Next reporting dateJuly 19, 2016
EPS forecast (this quarter)$4.67
Annual revenue (last year)$9.3B
Annual profit (last year)$3.5B
Net profit margin38.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
George A. Scangos
Chief Scientific Officer &
Executive VP
Spyridon Artavanis-Tsakonas
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs